Subtype
Esophageal Adenocarcinoma
CI-CAN-00005190Explore in graph →
70 active trials2 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005190Explore in graph →
Clinical trials
181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (27)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04499924 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer(MOUNTAINEER-02) | completed | Phase 2 / Phase 3 | 17 | Seagen Inc.INDUSTRY | 6 | Jan 22, 2025 |
| clinicaltrials |
| NCT01404156 | Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma(POWERRANGER) | completed | Phase 2 / Phase 3 | 29 | Dr. Gordon BuduhanOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT02830594 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 14 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03783936 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | completed | Phase 2 | 18 | Ashwin SomasundaramOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT02971956 | Pembrolizumab in Refractory Advanced Esophageal Cancer | completed | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT00591123 | Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia | completed | Phase 2 | 38 | Translational Oncology Research InternationalOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT02128243 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer(MATEO) | completed | Phase 2 | 242 | AIO-Studien-gGmbHOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01362127 | Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia(NeoRes) | completed | Phase 2 | 181 | Karolinska University HospitalOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT01612546 | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 10 | City of Hope Medical CenterOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT01178944 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT01231399 | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | completed | Phase 1 / Phase 2 | 6 | City of Hope Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01129206 | Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2016 | clinicaltrials |
| NCT01932580 | Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma | completed | Phase 2 | 10 | McGill UniversityOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00165490 | Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 10, 2014 | clinicaltrials |
| NCT00077545 | 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00045526 | Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00165191 | Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2009 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials